Join Growin Stock Community!

Thermo fisher scientific inc.TMO.US Overview

US StockHealthcare
(No presentation for TMO)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

TMO AI Insights

TMO Overall Performance

TMO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

TMO Recent Performance

-2.40%

Thermo fisher scientific inc.

0.05%

Avg of Sector

-0.31%

S&P500

TMO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

TMO Key Information

TMO Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

TMO Profile

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Price of TMO

TMO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

TMO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
17.84
PE Ratio (TTM)
29.41
Forward PE
19.77
PS Ratio (TTM)
4.39
PB Ratio
3.66
Price-to-FCF
30.15
METRIC
VALUE
vs. INDUSTRY
Gross Margin
40.93%
Net Margin
15.05%
Revenue Growth (YoY)
3.91%
Profit Growth (YoY)
3.03%
3-Year Revenue Growth
2.18%
3-Year Profit Growth
2.85%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
17.84
PE Ratio (TTM)
29.41
Forward PE
19.77
PS Ratio (TTM)
4.39
PB Ratio
3.66
Price-to-FCF
30.15
Gross Margin
40.93%
Net Margin
15.05%
Revenue Growth (YoY)
3.91%
Profit Growth (YoY)
3.03%
3-Year Revenue Growth
2.18%
3-Year Profit Growth
2.85%

  • When is TMO's latest earnings report released?

    The most recent financial report for Thermo fisher scientific inc. (TMO) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating TMO's short-term business performance and financial health. For the latest updates on TMO's earnings releases, visit this page regularly.

  • Where does TMO fall in the P/E River chart?

    According to historical valuation range analysis, Thermo fisher scientific inc. (TMO)'s current price-to-earnings (P/E) ratio is 28.82, placing it in the Reasonable zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of TMO?

    According to the latest financial report, Thermo fisher scientific inc. (TMO) reported an Operating Profit of 2.26B with an Operating Margin of 18.48% this period, representing a growth of 11.9% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is TMO's revenue growth?

    In the latest financial report, Thermo fisher scientific inc. (TMO) announced revenue of 12.22B, with a Year-Over-Year growth rate of 7.2%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does TMO have?

    As of the end of the reporting period, Thermo fisher scientific inc. (TMO) had total debt of 39.39B, with a debt ratio of 0.36. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does TMO have?

    At the end of the period, Thermo fisher scientific inc. (TMO) held Total Cash and Cash Equivalents of 9.85B, accounting for 0.09 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does TMO go with three margins increasing?

    In the latest report, Thermo fisher scientific inc. (TMO) achieved the “three margins increasing” benchmark, with a gross margin of 41%%, operating margin of 18.48%%, and net margin of 16.1%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess TMO's profit trajectory and future growth potential.

  • Is TMO's EPS continuing to grow?

    According to the past four quarterly reports, Thermo fisher scientific inc. (TMO)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 5.22. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of TMO?

    Thermo fisher scientific inc. (TMO)'s Free Cash Flow (FCF) for the period is 3.02B, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 6.79% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of TMO?

    The latest valuation data shows Thermo fisher scientific inc. (TMO) has a Price-To-Earnings (PE) ratio of 28.82 and a Price/Earnings-To-Growth (PEG) ratio of 1.26. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.